Anti-CD3 Monoclonal Antibody Otelixizumab in T1D
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Diabetologia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomised, Single-Blind, Placebo-Controlled, Dose-Finding Safety and Tolerability Study of the Anti-CD3 Monoclonal Antibody Otelixizumab in New-Onset Type 1 Diabetes
Diabetologia 2021 Feb 01;64(2)313-324, B Keymeulen, A van Maurik, D Inman, J Oliveira, R McLaughlin, RM Gittelman, BO Roep, P Gillard, R Hilbrands, F Gorus, C Mathieu, U Van de Velde, N Wisniacki, A NapolitanoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.